New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure.

Agnieszka Dębska-Kozłowska, Marcin Książczyk, Małgorzata Lelonek

Journal: Advances in medical sciences 2022;67(1):95-102

PMID: 35101654

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

Patients with acute decompensated heart failure (ADHF) are at severe risk of death and rehospitalization. Several clinical studies have been designed to evaluate the efficacy and safety of new molecules administered before discharge or shortly after ADHF. The aim of this article is to summarize current knowledge on recently published findings on treatment of patients with heart failure with reduced ejection fraction (HFrEF) and ADHF.

METHODS

We performed a thorough search for literature pertaining to our review via the PubMed database.

RESULTS

In this review, we summarize original papers concerning the efficacy and safety of new molecules in patients with HFrEF and ADHF.

CONCLUSIONS

Peri-discharge initiation of treatment with new molecules is possible and safe for patients with HFrEF and ADHF. New molecules, if administered before discharge or shortly after, reduce the risk of cardiovascular death or worsening heart failure within the vulnerable phase, and are also nephroprotective.

Address: Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz - Central Veterans' Hospital, Lodz, Poland.; Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland. Electronic address: [email protected].; Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland.

DOI: 10.1016/j.advms.2022.01.003

Link outs

Free resources

Medical:

https://medlineplus.gov/heartfailure.html

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1896...

MeSH Terms: Heart Failure, Humans, Stroke Volume